1. Home
  2. MRKR

as 06-05-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Founded: N/A Country:
United States
United States
Employees: N/A City: HOUSTON
Market Cap: 13.4M IPO Year: N/A
Target Price: $13.17 AVG Volume (30 days): 181.1K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.34 EPS Growth: N/A
52 Week Low/High: $0.95 - $5.99 Next Earning Date: 05-15-2025
Revenue: $5,696,123 Revenue Growth: 71.53%
Revenue Growth (this year): -59.78% Revenue Growth (next year): 11.28%

MRKR Daily Stock ML Predictions

Share on Social Networks: